|1.||Hopkins, Robert J: 6 articles (11/2014 - 08/2011)|
|2.||Quinn, Conrad P: 5 articles (07/2015 - 11/2010)|
|3.||Nabors, Gary S: 5 articles (11/2013 - 01/2007)|
|4.||Rudge, Thomas L: 4 articles (11/2013 - 11/2010)|
|5.||Pittman, Phillip R: 4 articles (10/2013 - 06/2005)|
|6.||Niemuth, Nancy A: 3 articles (07/2015 - 11/2010)|
|7.||Schiffer, Jarad M: 3 articles (07/2015 - 11/2010)|
|8.||Sabourin, Carol L: 3 articles (07/2015 - 11/2010)|
|9.||Howard, Cris: 3 articles (04/2014 - 07/2013)|
|10.||Ionin, Boris: 3 articles (11/2013 - 07/2013)|
08/26/2011 - "Immunization with BioThrax(®) (Anthrax Vaccine Adsorbed) is a safe and effective means of preventing anthrax. "
04/01/2015 - "A noninferiority study comparing the efficacy of AdVAV to the currently licensed Anthrax Vaccine Absorbed (AVA; BioThrax) was performed in New Zealand White rabbits using postchallenge survival as the study endpoint (20% noninferiority margin for survival). "
04/17/2014 - "This study was conducted to support licensure of a post-exposure prophylaxis indication for BioThrax(®) (anthrax vaccine adsorbed) concurrent with antimicrobials for individuals exposed to aerosolized anthrax spores. "
12/18/2013 - "In both human B cells and B cells from mice transgenic for human FcγRIIc, FcγRIIc expression counterbalances the negative feedback of FcγRIIb and enhances humoral responses to immunization in mice and to BioThrax vaccination in a human anthrax vaccine trial. "
04/12/2007 - "The vaccine and biodefense communities almost experienced the rare chance in a Phase I study to scientifically compare head-to-head an early-stage, investigational recombinant anthrax vaccine (rPA102) with the safe, effective and already FDA-licensed anthrax vaccine, AVA (BioThrax). "
02/28/2012 - "The principal application of this assay was in a Phase 4 human clinical trial of anthrax vaccine adsorbed (AVA, BioThrax), the central component of the CDC Anthrax Vaccine Research Program (AVRP) and in humans following bioterrorism associated Bacillus anthracis infection (Quinn et al., 2002; Quinn et al., 2004; Marano et al., 2008). "
07/17/2015 - "Anthrax Vaccine Adsorbed (AVA, BioThrax) is approved for use in humans as a priming series of 3 intramuscular (i.m.) injections (0, 1, 6 months; 3-IM) with boosters at 12 and 18 months, and annually thereafter for those at continued risk of infection. "
|2.||ProMune (CpG 7909)
|5.||anthrax toxin (anthrax lethal factor)
|6.||Immunoglobulin G (IgG)
|8.||Aluminum Hydroxide (Algeldrate)